Keros Therapeutics (NASDAQ:KROS) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Analysts at Cantor Fitzgerald began coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a note issued to investors on Thursday, Briefing.com reports. The brokerage set an “overweight” rating on the stock.

KROS has been the subject of several other reports. Bank of America lowered their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Scotiabank assumed coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Finally, Guggenheim began coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $89.11.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $57.99 on Thursday. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -11.26 and a beta of 1.23. Keros Therapeutics has a 12 month low of $27.02 and a 12 month high of $73.00. The stock’s 50-day moving average is $54.33 and its 200-day moving average is $51.94.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The business had revenue of $0.04 million during the quarter. During the same quarter last year, the firm earned ($1.27) EPS. Research analysts anticipate that Keros Therapeutics will post -4.88 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Keros Therapeutics during the third quarter valued at approximately $89,000. Assenagon Asset Management S.A. lifted its holdings in Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of Keros Therapeutics by 21.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 9,700 shares of the company’s stock worth $563,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Keros Therapeutics in the 2nd quarter worth approximately $128,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.